Paper31392201
An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.
Korlimarla A and 3 others. Ann Transl Med, 2019. Cited by 66 papers, by iCite.
Cite this record
ConductScience Library. An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. Papers, record 31392201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31392201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References91
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10513698 | Hydrocephalus associated with glycogen storage disease type II (Pompe's disease). | Pediatr Neurol | 1999 | https://conductscience.org/library/papers/10513698 | PubMed |
| 2 | 10547605 | Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. | J Pathol | 1999 | https://conductscience.org/library/papers/10547605 | PubMed |
| 3 | 1055118 | Generalized glycogen storage disease in sheep. | J Comp Pathol | 1975 | https://conductscience.org/library/papers/1055118 | PubMed |
| 4 | 10838256 | Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. | Neuromuscul Disord | 2000 | https://conductscience.org/library/papers/10838256 | PubMed |
| 5 | 11552029 | Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. | Neurology | 2001 | https://conductscience.org/library/papers/11552029 | PubMed |
| 6 | 12192090 | Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/12192090 | PubMed |
| 7 | 12897283 | The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. | Pediatrics | 2003 | https://conductscience.org/library/papers/12897283 | PubMed |
| 8 | 14253576 | POMPE'S DISEASE (DIFFUSE GLYCOGENOSIS) WITH NEURONAL STORAGE. | J Neuropathol Exp Neurol | 1965 | https://conductscience.org/library/papers/14253576 | PubMed |
| 9 | 15366815 | Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. | Chang Gung Med J | 2004 | https://conductscience.org/library/papers/15366815 | PubMed |
| 10 | 16212810 | The role of pericytes in blood-vessel formation and maintenance. | Neuro Oncol | 2005 | https://conductscience.org/library/papers/16212810 | PubMed |
| 11 | 16702877 | Pompe disease diagnosis and management guideline. | Genet Med | 2006 | https://conductscience.org/library/papers/16702877 | PubMed |
| 12 | 16713360 | Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. | Mol Ther | 2006 | https://conductscience.org/library/papers/16713360 | PubMed |
| 13 | 16857770 | Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. | Pediatr Res | 2006 | https://conductscience.org/library/papers/16857770 | PubMed |
| 14 | 16987711 | Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. | Mol Ther | 2006 | https://conductscience.org/library/papers/16987711 | PubMed |
| 15 | 17075580 | Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. | Lab Invest | 2006 | https://conductscience.org/library/papers/17075580 | PubMed |
| 16 | 17151339 | Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. | Neurology | 2007 | https://conductscience.org/library/papers/17151339 | PubMed |
| 17 | 17510371 | Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model. | J Histochem Cytochem | 2007 | https://conductscience.org/library/papers/17510371 | PubMed |
| 18 | 18414476 | Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. | Mol Ther | 2008 | https://conductscience.org/library/papers/18414476 | PubMed |
| 19 | 18471801 | Classification of white matter lesions on magnetic resonance imaging in elderly persons. | Biol Psychiatry | 2008 | https://conductscience.org/library/papers/18471801 | PubMed |
| 20 | 18648322 | Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. | J Neuropathol Exp Neurol | 2008 | https://conductscience.org/library/papers/18648322 | PubMed |
Cited by49
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42701350 | Epilepsy Is Part of the CNS Phenotype in Classic Infantile Pompe Disease. | Neurol Genet | 2026 | https://conductscience.org/library/papers/42701350 | PubMed |
| 42074341 | Pompe Disease: Pathogenesis, Molecular Mechanisms, Neurological Aspects, Diagnostics and Modern Therapeutic Approaches. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074341 | PubMed |
| 41720458 | Mapping glycogen accumulation and treatment effect in Pompe disease with saturation transfer MRI. | Transl Res | 2026 | https://conductscience.org/library/papers/41720458 | PubMed |
| 41622854 | Longitudinal characterization of Gaac.1826dupA mice reveals the cardiac, myopathic and biochemical phenotypes of Pompe disease. | Dis Model Mech | 2026 | https://conductscience.org/library/papers/41622854 | PubMed |
| 41483684 | Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease. | EBioMedicine | 2026 | https://conductscience.org/library/papers/41483684 | PubMed |
| 41148004 | A retrospective cohort study describing the disease burden in patients with Pompe disease treated with enzyme replacement therapy in the United States. | J Neuromuscul Dis | 2026 | https://conductscience.org/library/papers/41148004 | PubMed |
| 40927766 | A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40927766 | PubMed |
| 40893165 | Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40893165 | PubMed |
| 40518673 | Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease. | Mol Ther | 2025 | https://conductscience.org/library/papers/40518673 | PubMed |
| 40329530 | Current clinical applications of AAV-mediated gene therapy. | Mol Ther | 2025 | https://conductscience.org/library/papers/40329530 | PubMed |
| 40268518 | Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease. | Clin Transl Med | 2025 | https://conductscience.org/library/papers/40268518 | PubMed |
| 40183436 | Management of Pompe disease alongside and beyond ERT: a narrative review. | Acta Myol | 2025 | https://conductscience.org/library/papers/40183436 | PubMed |
| 39949979 | Gene therapy for genetic diseases: challenges and future directions. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/39949979 | PubMed |
| 39859472 | Highlights of Precision Medicine, Genetics, Epigenetics and Artificial Intelligence in Pompe Disease. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39859472 | PubMed |
| 39817232 | Expanding therapeutic options for Pompe disease: a new small molecule inhibitor of glycogen synthase 1 (GYS1) shows preclinical promise in Pompe disease. | Ann Transl Med | 2024 | https://conductscience.org/library/papers/39817232 | PubMed |
| 39309683 | Brain glycogen build-up measured by magnetic resonance spectroscopy in classic infantile Pompe disease. | Brain Commun | 2024 | https://conductscience.org/library/papers/39309683 | PubMed |
| 39295144 | Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations. | Mol Ther | 2024 | https://conductscience.org/library/papers/39295144 | PubMed |
| 39277505 | Neurological glycogen storage diseases and emerging therapeutics. | Neurotherapeutics | 2024 | https://conductscience.org/library/papers/39277505 | PubMed |
| 38948331 | Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells. | Mol Ther Nucleic Acids | 2024 | https://conductscience.org/library/papers/38948331 | PubMed |
| 38248833 | Altered Sphingolipid Hydrolase Activities and Alpha-Synuclein Level in Late-Onset Schizophrenia. | Metabolites | 2023 | https://conductscience.org/library/papers/38248833 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GAA | 2548 | PubTator's text mining | https://conductscience.org/library/genes/2548 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31392201
GET https://conductscience.org/api/papers/v1/31392201/references?page=2